Preventive treatment for bleeding in hemophilia
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new medicine called SR604, given as a shot under the skin, to help prevent bleeding in people with hemophilia A or B. If it works, it could reduce the number of bleeding episodes and make daily life easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 65 years old.
- You have hemophilia A (with very low factor VIII) or hemophilia B (with very low factor IX).
- You have had at least 6 bleeding episodes in the last 6 months that needed treatment.
- You have either no inhibitors or high inhibitors, with specific treatment history.
- You are willing to follow the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
This study tests a new medicine called KN057 for people with hemophilia A or B, with or without inhibitors, to see if it helps prevent bleeding. It is for people who still have frequent bleeding episodes despite current treatments.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.